会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • 꾸지뽕나무 줄기 추출물을 함유하는 아토피 질환 치료용 조성물
    • 包含作为预防和治疗原发性疾病的活性成分的CUDAIA TRICUSPIDATA TRUNK的提取物的组合物
    • KR1020130019352A
    • 2013-02-26
    • KR1020120087480
    • 2012-08-09
    • 한양대학교 산학협력단
    • 강주섭박유신서주환
    • A61K36/605A61P17/00
    • A61K36/605A23L33/105A23V2002/00A23V2200/324
    • PURPOSE: A composition containing a Cudrania tricuspidata stem extract is provided to effectively treat inflammation or prevent skin lesion due to atopic dermatitis. CONSTITUTION: A composition for preventing and treating atopic dermatitis contains a Cudrania tricuspidata stem extract as an active ingredient. The extract is prepared by extracting Cudrania tricuspidata with water, low carbon number alcohol, or a mixture thereof. The low carbon number alcohol is ethanol or methanol. The extract contains quercetin, kaempferol, and an ingredient which is detected at absorbance 370nm and 7.8min as main ingredients. A health functional food for preventing and treating atopic dermatitis contains the extract as an active ingredient.
    • 目的:提供含有三头螨柄提取物的组合物,以有效治疗炎症或预防由于特应性皮炎引起的皮肤损伤。 构成:用于预防和治疗特应性皮炎的组合物含有三头ata提取物作为活性成分。 该提取物是通过用水,低碳数醇或其混合物提取三叉戟草制备的。 低碳数醇是乙醇或甲醇。 提取物含有槲皮素,山奈酚和以吸光度370nm和7.8min为主要成分的成分。 用于预防和治疗特应性皮炎的健康功能食品含有提取物作为活性成分。
    • 4. 发明公开
    • 간 질환 치료용 혈류 의존성 약물의 용량 결정 방법
    • 一种确定用于治疗肝病的血液依赖药物剂量的方法
    • KR1020130055548A
    • 2013-05-28
    • KR1020120130855
    • 2012-11-19
    • 한양대학교 산학협력단주식회사 엠케이제약
    • 이민호강주섭류성언최윤영곽민정함윤식최인옥
    • A61M5/14A61J7/00
    • A61M2005/14288Y10S514/893
    • PURPOSE: A capacity decision method of blood flow dependability drug for liver disease treatment is provided to be the index of necessary capacity determination according to the severity of liver disease and get the most reasonable AUC and Cmax value. CONSTITUTION: A capacity decision method of blood flow dependability drug according to the severity of liver disease is provided to use AUC(Area under the plasma concentration-time curve) and Cmax as an index. The AUC value is drawn by the equation 1. [Equation 1] F (AUC) = 591.3+349.9*H / L ratio-0.345*AST-0.892*ALT-39.45 * (AST/ALT ratio) +0.172*LDH. H/L ration is the rate of heart/ liver as a hepatic portal vein index, ALT(Alanine transaminase) and AST(Aspartic acid transaminase) are blood serum brine value, and LDH is lactate dehydrogenase value. [Reference numerals] (AA) First group; (BB) Second group; (CC) Third group
    • 目的:提供肝脏疾病治疗血流可靠性药物的能力决定方法,根据肝病严重程度确定必要的能力指标,得到最合理的AUC和Cmax值。 构成:提供根据肝脏疾病严重程度的血流可靠性药物的能力决定方法,使用AUC(血浆浓度 - 时间曲线下的面积)和Cmax作为指标。 AUC值由式(1)表示。[式1] F(AUC)= 591.3±349.9 * H / L比0.345 * AST-0.892 * ALT-39.45 *(AST / ALT比)+ 0.172×LDH。 肝/肝比例为肝门静脉指数,ALT(丙氨酸转氨酶)和AST(天冬氨酸转氨酶)为血清盐水值,LDH为乳酸脱氢酶值。 (附图标记)(AA)第一组; (BB)第二组; (CC)第三组